[go: nahoru, domu]

SG10201607891VA - Corticosteroids for the treatment of joint pain - Google Patents

Corticosteroids for the treatment of joint pain

Info

Publication number
SG10201607891VA
SG10201607891VA SG10201607891VA SG10201607891VA SG10201607891VA SG 10201607891V A SG10201607891V A SG 10201607891VA SG 10201607891V A SG10201607891V A SG 10201607891VA SG 10201607891V A SG10201607891V A SG 10201607891VA SG 10201607891V A SG10201607891V A SG 10201607891VA
Authority
SG
Singapore
Prior art keywords
corticosteroids
treatment
joint pain
pain
joint
Prior art date
Application number
SG10201607891VA
Inventor
Neil Bodick
Robert C Blanks
Anjali Kumar
Michael D Clayman
Mark Moran
Original Assignee
Flexion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flexion Therapeutics Inc filed Critical Flexion Therapeutics Inc
Publication of SG10201607891VA publication Critical patent/SG10201607891VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG10201607891VA 2010-08-04 2011-08-04 Corticosteroids for the treatment of joint pain SG10201607891VA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37066610P 2010-08-04 2010-08-04

Publications (1)

Publication Number Publication Date
SG10201607891VA true SG10201607891VA (en) 2016-11-29

Family

ID=45559826

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201607891VA SG10201607891VA (en) 2010-08-04 2011-08-04 Corticosteroids for the treatment of joint pain
SG10201602789XA SG10201602789XA (en) 2010-08-04 2011-08-04 Corticosteroids for the treatment of joint pain
SG2013007703A SG187665A1 (en) 2010-08-04 2011-08-04 Corticosteroids for the treatment of joint pain

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10201602789XA SG10201602789XA (en) 2010-08-04 2011-08-04 Corticosteroids for the treatment of joint pain
SG2013007703A SG187665A1 (en) 2010-08-04 2011-08-04 Corticosteroids for the treatment of joint pain

Country Status (23)

Country Link
US (8) US20120282298A1 (en)
EP (2) EP2600836B1 (en)
JP (3) JP5873492B2 (en)
KR (2) KR20180132159A (en)
CN (2) CN103260603B (en)
AR (1) AR082471A1 (en)
AU (1) AU2011285691B2 (en)
BR (1) BR112013002601A2 (en)
CA (2) CA2956556A1 (en)
CL (1) CL2013000347A1 (en)
CO (1) CO6700827A2 (en)
ES (1) ES2799419T3 (en)
IL (1) IL224547B (en)
MX (1) MX353466B (en)
MY (1) MY171929A (en)
NZ (1) NZ607797A (en)
RU (2) RU2642279C2 (en)
SG (3) SG10201607891VA (en)
TW (2) TWI630001B (en)
UA (1) UA111162C2 (en)
UY (1) UY33546A (en)
WO (1) WO2012019009A1 (en)
ZA (1) ZA201300831B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111162C2 (en) * 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. INJECTION COMPOSITION OF TRIAMCINOLONE ACETONIDE FOR TREATMENT OF PAIN
CA2832663C (en) 2011-04-25 2016-02-09 Shandong Luye Pharmaceutical Co., Ltd. Risperidone sustained release microsphere composition
EP2739287B1 (en) * 2011-08-04 2017-07-05 Flexion Therapeutics, Inc. Corticosteroids for the treatment of joint pain
US8927529B2 (en) * 2012-01-30 2015-01-06 SpineThera Treatment of back pain by injection of microparticles of dexamethasone acetate and a polymer
BR112015017246B1 (en) 2013-01-23 2022-11-29 Semnur Pharmaceuticals, Inc INJECTABLE AQUEOUS PHARMACEUTICAL COMPOSITION, ITS USE AND SYRINGE
JP2016515517A (en) * 2013-03-15 2016-05-30 オークウッド ラボラトリーズ，エル．エル．シー． Sustained release microsphere and method for producing the same
WO2014153384A1 (en) * 2013-03-19 2014-09-25 Flexion Therapeutics, Inc. Corticosteroid formulations for the treatment of joint pain and methods of use thereof
AU2014235854B2 (en) * 2013-03-21 2019-04-11 Eupraxia Pharmaceuticals USA LLC Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
WO2015018461A1 (en) * 2013-08-09 2015-02-12 Genbiotech Therapeutic compositions comprising hyaluronic acid
US10058637B2 (en) * 2013-11-27 2018-08-28 Ethicon, Llc Absorbable polymeric blend compositions with precisely controllable absorption rates, processing methods, and dimensionally stable medical devices therefrom
US20170119813A1 (en) * 2014-04-08 2017-05-04 Dsm Ip Assets B.V. Biodegradable polyesteramide used for the treatment of arthritic disorders
TWI845973B (en) 2015-01-21 2024-06-21 美商桑紐爾製藥公司 Pharmaceutical formulation
CA2987209A1 (en) * 2015-06-10 2016-12-15 Evonik Rohm Gmbh Process for preparing a powder comprising a human coagulation factor protein and a lactic acid polymer
EP3352735B1 (en) 2015-09-21 2023-08-30 Teva Pharmaceuticals International GmbH Sustained release olanzapine formulations
UY36948A (en) * 2015-10-13 2017-05-31 Flexion Therapeutics Inc CORTICOSTEROID FORMULATIONS TO MAINTAIN CORTICOSTEROID CONCENTRATIONS IN THE SYNOVIAL LIQUID
ES2672993T3 (en) 2015-10-27 2018-06-19 Eupraxia Pharmaceuticals Inc. Sustained release formulations of local anesthetics
WO2017160818A1 (en) 2016-03-14 2017-09-21 Flexion Therapeutics, Inc. Triamcinolone acetonide formulations for joint pain in diabetics
WO2018112408A1 (en) * 2016-12-15 2018-06-21 Flexion Therapeutics, Inc. Fluticasone formulations and methods of use thereof
CN106727358A (en) * 2017-01-24 2017-05-31 广州帝奇医药技术有限公司 The slow releasing composition of Aripiprazole and its derivative and the preparation method of the slow releasing composition
CN106983733A (en) * 2017-03-08 2017-07-28 江苏富泽药业有限公司 Triamcinolone acetonide PLGA sustained-release microspheres injections, its preparation method and its application in treatment osteo-arthritic pain medicine is prepared
EP3595776A4 (en) * 2017-03-17 2020-09-30 Flexion Therapeutics, Inc. Fluticasone extended-release formulations and methods of use thereof
AU2018238136A1 (en) 2017-03-20 2019-11-07 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations
KR102101969B1 (en) * 2017-09-06 2020-04-22 (주)인벤티지랩 Microparticles containing moxidectin and method for manufacturing same
US20190336511A1 (en) * 2018-05-02 2019-11-07 Georgiy Brusovanik Treatment for Inflammation and Pain with Reduced Gastro-Intestinal Side Effects Combining Methylprednisolone, Paracetamol, and Lansoprazole
AU2019301542A1 (en) 2018-07-09 2021-02-25 Tlc Biopharmaceuticals, Inc. Methods to reduce complications of intra-articular steroid
RU2703257C1 (en) * 2018-12-04 2019-10-16 Закрытое акционерное общество "СКАЙ ЛТД" Method of treating inflammatory processes of joints and prostatitis
CN109700770B (en) * 2019-01-31 2021-02-12 浙江圣兆药物科技股份有限公司 Triamcinolone acetonide microsphere preparation and preparation method thereof
KR102377975B1 (en) * 2019-03-19 2022-03-23 (주)리젠바이오텍 Biodegradable polymer microparticles containing steroid drugs and a method for manufacturing the same
JP7296520B2 (en) * 2019-03-19 2023-06-22 株式会社リーゼンバイオテク Biodegradable polymer microparticles containing steroid drug and method for producing the same
CN113795246B (en) * 2019-05-06 2024-10-11 福多兹制药公司 Injectable sustained release formulation for the treatment of joint pain and inflammation
WO2020243608A1 (en) * 2019-05-31 2020-12-03 Dose Medical Corporation Bioerodible polyester polymer implants and related methods of use
CN110237052B (en) * 2019-07-11 2021-07-13 苏州大学 Triamcinolone acetonide acetate sustained-release microsphere and preparation method thereof
CN111803647A (en) * 2020-08-14 2020-10-23 山东谷雨春生物科技有限公司 Medicine for treating degenerative arthritis and preparation method thereof
WO2022153262A1 (en) 2021-01-18 2022-07-21 Anton Frenkel Pharmaceutical dosage form
GB202104224D0 (en) 2021-03-25 2021-05-12 Medincell Pharmaceutical composition
JP2024511072A (en) * 2021-03-26 2024-03-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Immunomodulatory microparticles for modulating inflammatory arthritis
WO2022219089A1 (en) 2021-04-16 2022-10-20 Fondazione Istituto Italiano Di Tecnologia Polymeric microparticles for the local treatment of chronic inflammatory diseases
JP2024529009A (en) 2021-07-06 2024-08-01 マーク・ヘースルトン Treatment of serotonin reuptake inhibitor withdrawal syndrome
WO2024085581A1 (en) * 2022-10-17 2024-04-25 (주)인벤티지랩 Sustained-release injectable composition for treating or preventing inflammatory disease, and method for preparing same

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4293539A (en) 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
US4530840A (en) * 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US5700485A (en) * 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
EP0724433B1 (en) 1993-10-22 1998-12-30 Genentech, Inc. Method for preparing microspheres comprising a fluidized bed drying step
PT729353E (en) 1993-11-19 2002-07-31 Alkermes Inc PREPARATION OF BIODEGRADABLE MICROPARTICLES CONTAINING A BIOLOGICALLY ACTIVE AGENT
DE69841984D1 (en) 1997-09-05 2010-12-16 Maruho K K COMPOSITION OF NANOCAPSULES FOR THE TREATMENT OF INTRAARTICULAR DISEASES
JPH11222425A (en) * 1997-10-27 1999-08-17 Ss Pharmaceut Co Ltd Intra-articular injection preparation for treating articular disease
TW577758B (en) * 1997-10-27 2004-03-01 Ssp Co Ltd Intra-articular preparation for the treatment of arthropathy
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US20040043964A1 (en) 2000-11-06 2004-03-04 Gomi Shun?Apos;Ichi Cellulosic particle for pharmaceuticals preparation
KR100446101B1 (en) 2000-12-07 2004-08-30 주식회사 삼양사 Sustained delivery composition for poorly water soluble drugs
JP2004516262A (en) 2000-12-21 2004-06-03 ネクター セラピューティクス Induced phase transition method for the production of microparticles containing hydrophilic activators
US20040022853A1 (en) 2001-04-26 2004-02-05 Control Delivery Systems, Inc. Polymer-based, sustained release drug delivery system
CN1694689A (en) * 2002-09-30 2005-11-09 阿库斯菲尔公司 Sustained release pharmaceutical formulation for inhalation
CA2501298A1 (en) 2002-10-17 2004-04-29 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
US7544192B2 (en) 2003-03-14 2009-06-09 Sinexus, Inc. Sinus delivery of sustained release therapeutics
US20040224030A1 (en) * 2003-05-06 2004-11-11 Shastri Venkatram R. Microsphere delivery systems
JP2007500243A (en) 2003-06-09 2007-01-11 ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド Compositions and methods for enhanced transmucosal delivery of growth hormone
CA2533887A1 (en) * 2003-09-30 2005-04-14 Acusphere, Inc. Injectable, oral, or topical sustained release pharmaceutical formulations
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20090324678A1 (en) * 2004-07-16 2009-12-31 Spinal Restoration, Inc. Methods and kits for treating joints and soft tissues
US9693967B2 (en) * 2005-09-07 2017-07-04 Southwest Research Institute Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates
US7758778B2 (en) 2005-09-07 2010-07-20 Southwest Research Institute Methods for preparing biodegradable microparticle formulations containing pharmaceutically active agents
JP2009507845A (en) 2005-09-07 2009-02-26 サウスウエスト リサーチ インスティテュート Biodegradable microparticle pharmaceutical formulation with improved release rate
US7261529B2 (en) 2005-09-07 2007-08-28 Southwest Research Institute Apparatus for preparing biodegradable microparticle formulations containing pharmaceutically active agents
CA2636716C (en) 2006-01-13 2014-12-23 Surmodics, Inc. Microparticle containing matrices for drug delivery
US20070298073A1 (en) * 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
AU2007319577A1 (en) * 2006-10-06 2008-05-22 Baxter Healthcare S.A. Microencapsules containing surface-modified microparticles and methods of forming and using the same
US20080317805A1 (en) * 2007-06-19 2008-12-25 Mckay William F Locally administrated low doses of corticosteroids
AU2008288772A1 (en) * 2007-08-23 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
US20110206773A1 (en) 2008-05-20 2011-08-25 Yale University Sustained delivery of drugs from biodegradable polymeric microparticles
WO2009150136A1 (en) 2008-06-09 2009-12-17 Boehringer Ingelheim International Gmbh Novel embedment particles for inhalation
JP5757872B2 (en) * 2008-09-11 2015-08-05 エボニック コーポレイションＥｖｏｎｉｋ Ｃｏｒｐｏｒａｔｉｏｎ Solvent extraction microencapsulation with adjustable extraction rate
JP2012515791A (en) 2009-01-23 2012-07-12 サーモディクス ファーマシューティカルズ， インコーポレイテッド Controlled release system derived from polymer hybrids
EA201290497A1 (en) 2009-12-15 2013-01-30 Байнд Байосайенсиз, Инк. THERAPEUTIC POLYMERIC NANOPARTICLES, INCLUDING CORTICOSTEROIDS, AND METHODS OF OBTAINING SUCH
UA111162C2 (en) 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. INJECTION COMPOSITION OF TRIAMCINOLONE ACETONIDE FOR TREATMENT OF PAIN

Also Published As

Publication number Publication date
NZ607797A (en) 2014-12-24
CA2807150C (en) 2017-03-14
EP2600836A1 (en) 2013-06-12
CA2807150A1 (en) 2012-02-09
US20140356437A1 (en) 2014-12-04
RU2642279C2 (en) 2018-01-24
JP2016028070A (en) 2016-02-25
TWI630001B (en) 2018-07-21
US20180311260A1 (en) 2018-11-01
JP2013535489A (en) 2013-09-12
AR082471A1 (en) 2012-12-12
JP2019059752A (en) 2019-04-18
UY33546A (en) 2012-02-29
US20150025050A1 (en) 2015-01-22
CO6700827A2 (en) 2013-06-28
EP2600836A4 (en) 2014-01-15
US9949987B2 (en) 2018-04-24
WO2012019009A1 (en) 2012-02-09
AU2011285691A1 (en) 2013-03-21
US20120282298A1 (en) 2012-11-08
ZA201300831B (en) 2014-10-29
MX2013001433A (en) 2013-06-03
SG10201602789XA (en) 2016-05-30
BR112013002601A2 (en) 2016-06-07
CA2956556A1 (en) 2012-02-09
IL224547B (en) 2020-09-30
MX353466B (en) 2018-01-12
MY171929A (en) 2019-11-07
RU2018100114A (en) 2019-02-20
TW201703762A (en) 2017-02-01
TWI548412B (en) 2016-09-11
CN103260603B (en) 2017-11-10
US9555047B2 (en) 2017-01-31
RU2013109362A (en) 2014-09-10
CN103260603A (en) 2013-08-21
KR20130093101A (en) 2013-08-21
CN107669640A (en) 2018-02-09
UA111162C2 (en) 2016-04-11
AU2011285691B2 (en) 2015-10-01
TW201219039A (en) 2012-05-16
US10624905B2 (en) 2020-04-21
KR101927551B1 (en) 2018-12-10
CL2013000347A1 (en) 2013-09-06
EP3701941A1 (en) 2020-09-02
ES2799419T3 (en) 2020-12-17
US8828440B2 (en) 2014-09-09
US20120288534A1 (en) 2012-11-15
US20170182068A1 (en) 2017-06-29
US20170135957A1 (en) 2017-05-18
US9555048B2 (en) 2017-01-31
JP5873492B2 (en) 2016-03-01
EP2600836B1 (en) 2020-04-22
US20140242170A1 (en) 2014-08-28
KR20180132159A (en) 2018-12-11
SG187665A1 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
ZA201300831B (en) Corticosteroids for the treatment of joint pain
IL261768B (en) Devices and methods for the treatment of tissue
EP2621499A4 (en) Methods for the treatment of allergic diseases
HK1169804A1 (en) Methods for treatment of pain
HK1215787A1 (en) Pharmaceutical combination for the treatment of pain
EP2528603A4 (en) Pharmaceutical compositions for the treatment of pain and other indicatons
EP2654745A4 (en) Composition for the treatment of skin conditions
SG2014014724A (en) METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
IL225793A0 (en) Methods and compositions for the treatment of insulin-associated medical conditions
ZA201408055B (en) Compositions and methods for the treatment of local pain
IL225896A0 (en) Treatment of mecp2-associated disorders
EP2681209A4 (en) Compounds and methods for the treatment of pain and other disorders
ZA201305970B (en) Arylosulfonami for the treatment of cns diseases
ZA201301458B (en) Therapeutic agent for pain
IL225755B (en) 6-amidoderivatives of 4,5a-epoxymorphinans for treatment of pain
EP2556161A4 (en) Methods for the treatment of autoimmune diseases
EP2739287A4 (en) Corticosteroids for the treatment of joint pain
PT2460509T (en) Composition for the treatment of warts
SI2531124T1 (en) Devices for the treatment of skin lesions
PT2456445E (en) Agent for the treatment of skin conditions
GB201007205D0 (en) Treatment of joint disorders
GB201009194D0 (en) Treatment of pain
AU2011902407A0 (en) Treatment of pain